View Financial HealthZenith Capital 배당 및 자사주 매입배당 기준 점검 0/6Zenith Capital 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-22.1%자사주 매입 수익률총 주주 수익률-22.1%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Aug 05Zenith Capital Corp., Annual General Meeting, Oct 26, 2023Zenith Capital Corp., Annual General Meeting, Oct 26, 2023.공시 • Aug 13Zenith Capital Corp., Annual General Meeting, Oct 27, 2022Zenith Capital Corp., Annual General Meeting, Oct 27, 2022. Location: Calgary, AB Calgary Canada공시 • May 12Zenith Epigenetics Announces Initiation of Phase 2b Triple Negative Breast Cancer Clinical TrialZenith Epigenetics Ltd. announced the initiation of a Phase 2b Triple Negative Breast Cancer clinical trial combining ZEN-3694 + Pfizer Inc.'s Talzenna (talazoparib). The trial will continue to evaluate the efficacy and safety of this combination in patients with locally advanced or metastatic germline wild type BRCA1/2 TNBC. This Phase 2b trial is an extension of the recently completed Phase 1b/2 trial which met its primary efficacy endpoint of clinical benefit rate comprised of objective responses plus stable disease and which showed that the combination regimen was well tolerated. The Phase 2b extension will enroll patients who have previously been treated with a TROP2 antibody drug conjugate for locally advanced or metastatic disease. In the United States, talazoparib is currently approved under the brand name TALZENNA, which is a poly polymerase inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. Single agent PARPi are approved for gBRCAm HER2-negative locally advanced or metastatic breast cancer, as both PARP inhibition and non-functioning DNA repair proteins BRCA1/2 are required to block DNA repair and kill tumor cells (synthetic lethality). Preclinical and clinical data has shown that BET inhibition may reduce the levels of DNA repair proteins such as BRCA1/2 and RAD51 and thus create synthetic lethality in wildtype BRCA1/2 TNBC tumors when combined with PARP inhibition.공시 • Feb 01+ 1 more updateZenith Epigenetics Provides Clinical UpdateZenith Capital Corp. is developing various novel combinations of BET inhibitors with other targeted agents for numerous oncology indications in pre-selected or enriched patient populations. Company lead compound, ZEN-3694 is undergoing clinical development in multiple clinical trials: Phase 2b metastatic castration resistant prostate (mCRPC) cancer trialin combination with androgen receptor inhibitor, XTANDI (enzalutamide): Randomized trial comparing XTANDI in combination with ZEN-3694 to XTANDI treatment alone in patients with mCRPC. Conducted in collaboration Astellas Pharma and Newsoara Biopharma. This study is active and currently recruiting across multiple sites in the US and is in the activation stage in China. Differentiated study that will focus on addressing a significant unmet need in patients with AR independent tumors. Phase 2b Triple Negative Breast Cancer (TNBC) trial in combination with the PARP inhibitor TALZENNA (talazoparib): Conducted in collaboration with Pfizer and Newsoara Biopharma. This study is an expansion of the ongoing Phase 2 trial and is in the activation stage in US/EU/China. Based on discussions with US FDA, this Phase 2b trial – with a positive outcome – can potentially enable registration of ZEN-3694 via accelerated approval. Phase 1b/2 androgen receptor independent mCRPC trial in combination with immune checkpoint inhibitor KEYTRUDA (pembrolizumab) and XTANDI: Conducted in collaboration with Merck, the University of California, San Francisco, and the University of Michigan. Data to date shows that the combination can be dosed safely and is clinically active. The trial has progressed to the efficacy stage and is accruing well. Phase 1b/2 ovarian cancer trial in combination with immune-checkpoint inhibitors, nivolumab and ipilimumab: National Cancer Institute is conducting this trial in collaboration with Zenith and BMS. This is a second trial combining immune-checkpoint inhibitors with ZEN-3694. Expected to enroll first patient in the first quarter of 2022. Phase 1b/2 solid tumors and lymphoma trial in combination with entinostat: National Cancer Institute is conducting this trial in collaboration with Zenith and SyndaxExpected to enroll first patient in the first half of 2022.공시 • Jun 25Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate CancerZenith Capital Corp. announced the publication of an important study which has uncovered the role of ZEN-3694, a BET bromodomain inhibitor (BETi), in overcoming the resistance of metastatic castration resistant prostate cancer (mCRPC) to androgen receptor signaling inhibitors (ARSi). The study, led by a team of renowned prostate cancer researchers, has been published in Clinical Cancer Research, a high impact journal. The study demonstrated that mCRPC, when treated with ARSi, can switch its lineage from adenocarcinoma to a more aggressive neuroendocrine type which is less dependent on androgen receptor signaling. This treatment induced neuroendocrine prostate cancer is becoming more prevalent with increasing use of ARSis and is associated with very poor patient clinical outcomes. ZEN-3694 inhibits BRD4 and E2F1 which epigenetically regulate this lineage switch. Blocking BET bromodomain proteins in cell models stopped the activation of this program that drives the development of neuroendocrine prostate tumors, the research team found. Furthermore, this was supported by clinical data from ZEN-3694 Phase 1b/2a mCRPC study which showed that ZEN-3694 was most effective in patients whose tumors were less dependent on androgen receptor signaling and did not respond to prior ARSi. High expression of BRD4 and E2F1 were also observed in the tumors of two patients with treatment emergent neuroendocrine prostate cancer, and both patients had a response to ZEN-3694 + enzalutamide, consistent with the role of ZEN-3694 in overcoming resistance to ARSi in this aggressive form of prostate cancer.공시 • Mar 17Zenith Epigenetics Announces Dosing of First Mcrpc Patient with A Combination of Zen-3694 + Merck's Immune Check Point Inhibitor KeytrudaZenith Epigenetics Ltd. announced the dosing of first patient with a triple combination of ZEN-3694 + Merck's immune check point inhibitor, KEYTRUDA, + Pfizer's androgen receptor signaling inhibitor (ARSI), XTANDI, in a University of California, San Francisco (UCSF) investigator led metastatic castration resistant prostate cancer (mCRPC) Phase 2 clinical trial. ZEN-3694, the Company's lead therapeutic compound, is being developed for epigenetic combination therapies in multiple oncology indications. This clinical trial will evaluate the aforementioned triple combination therapy in mCRPC patients that have become resistant to 1st a 1 line ARSI therapy. These patients have a very poor prognosis and have a significant need for non-chemotherapies. This study is being supported in part by a research grant from the Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.공시 • Oct 06Zenith Epigenetics Announces Collaboration with Nci in Developing Zen-3694 for Multiple Oncology IndicationsZenith Epigenetics Ltd. announced the execution of a cooperative research and development agreement with the National Cancer Institute to develop ZEN-3694 for multiple oncology indications. For the first clinical study under the CRADA, NCI is co-collaborating with Zenith and Bristol Myers Squibb to investigate the combination of Zenith’s epigenetic therapy BET inhibitor ZEN-3694 with immuno-oncology therapies – checkpoint inhibitors nivolumab and ipilimumab – in resistant ovarian cancer.공시 • Oct 04Zenith Capital Corp. to Report Fiscal Year 2020 Results on Oct 12, 2020Zenith Capital Corp. announced that they will report fiscal year 2020 results on Oct 12, 2020공시 • Jul 19+ 3 more updatesZenith Capital Corp. Auditor Raises 'Going Concern' DoubtZenith Capital Corp. filed its Annual on Aug 25, 2014 for the period ending Apr 30, 2014. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ZHCL.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ZHCL.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Zenith Capital 배당 수익률 vs 시장ZHCL.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ZHCL.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Biotechs)2.5%분석가 예측 (ZHCL.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ZHCL.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ZHCL.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ZHCL.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ZHCL.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/17 10:12종가2026/06/17 00:00수익2026/01/31연간 수익2025/04/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Zenith Capital Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Aug 05Zenith Capital Corp., Annual General Meeting, Oct 26, 2023Zenith Capital Corp., Annual General Meeting, Oct 26, 2023.
공시 • Aug 13Zenith Capital Corp., Annual General Meeting, Oct 27, 2022Zenith Capital Corp., Annual General Meeting, Oct 27, 2022. Location: Calgary, AB Calgary Canada
공시 • May 12Zenith Epigenetics Announces Initiation of Phase 2b Triple Negative Breast Cancer Clinical TrialZenith Epigenetics Ltd. announced the initiation of a Phase 2b Triple Negative Breast Cancer clinical trial combining ZEN-3694 + Pfizer Inc.'s Talzenna (talazoparib). The trial will continue to evaluate the efficacy and safety of this combination in patients with locally advanced or metastatic germline wild type BRCA1/2 TNBC. This Phase 2b trial is an extension of the recently completed Phase 1b/2 trial which met its primary efficacy endpoint of clinical benefit rate comprised of objective responses plus stable disease and which showed that the combination regimen was well tolerated. The Phase 2b extension will enroll patients who have previously been treated with a TROP2 antibody drug conjugate for locally advanced or metastatic disease. In the United States, talazoparib is currently approved under the brand name TALZENNA, which is a poly polymerase inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. Single agent PARPi are approved for gBRCAm HER2-negative locally advanced or metastatic breast cancer, as both PARP inhibition and non-functioning DNA repair proteins BRCA1/2 are required to block DNA repair and kill tumor cells (synthetic lethality). Preclinical and clinical data has shown that BET inhibition may reduce the levels of DNA repair proteins such as BRCA1/2 and RAD51 and thus create synthetic lethality in wildtype BRCA1/2 TNBC tumors when combined with PARP inhibition.
공시 • Feb 01+ 1 more updateZenith Epigenetics Provides Clinical UpdateZenith Capital Corp. is developing various novel combinations of BET inhibitors with other targeted agents for numerous oncology indications in pre-selected or enriched patient populations. Company lead compound, ZEN-3694 is undergoing clinical development in multiple clinical trials: Phase 2b metastatic castration resistant prostate (mCRPC) cancer trialin combination with androgen receptor inhibitor, XTANDI (enzalutamide): Randomized trial comparing XTANDI in combination with ZEN-3694 to XTANDI treatment alone in patients with mCRPC. Conducted in collaboration Astellas Pharma and Newsoara Biopharma. This study is active and currently recruiting across multiple sites in the US and is in the activation stage in China. Differentiated study that will focus on addressing a significant unmet need in patients with AR independent tumors. Phase 2b Triple Negative Breast Cancer (TNBC) trial in combination with the PARP inhibitor TALZENNA (talazoparib): Conducted in collaboration with Pfizer and Newsoara Biopharma. This study is an expansion of the ongoing Phase 2 trial and is in the activation stage in US/EU/China. Based on discussions with US FDA, this Phase 2b trial – with a positive outcome – can potentially enable registration of ZEN-3694 via accelerated approval. Phase 1b/2 androgen receptor independent mCRPC trial in combination with immune checkpoint inhibitor KEYTRUDA (pembrolizumab) and XTANDI: Conducted in collaboration with Merck, the University of California, San Francisco, and the University of Michigan. Data to date shows that the combination can be dosed safely and is clinically active. The trial has progressed to the efficacy stage and is accruing well. Phase 1b/2 ovarian cancer trial in combination with immune-checkpoint inhibitors, nivolumab and ipilimumab: National Cancer Institute is conducting this trial in collaboration with Zenith and BMS. This is a second trial combining immune-checkpoint inhibitors with ZEN-3694. Expected to enroll first patient in the first quarter of 2022. Phase 1b/2 solid tumors and lymphoma trial in combination with entinostat: National Cancer Institute is conducting this trial in collaboration with Zenith and SyndaxExpected to enroll first patient in the first half of 2022.
공시 • Jun 25Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate CancerZenith Capital Corp. announced the publication of an important study which has uncovered the role of ZEN-3694, a BET bromodomain inhibitor (BETi), in overcoming the resistance of metastatic castration resistant prostate cancer (mCRPC) to androgen receptor signaling inhibitors (ARSi). The study, led by a team of renowned prostate cancer researchers, has been published in Clinical Cancer Research, a high impact journal. The study demonstrated that mCRPC, when treated with ARSi, can switch its lineage from adenocarcinoma to a more aggressive neuroendocrine type which is less dependent on androgen receptor signaling. This treatment induced neuroendocrine prostate cancer is becoming more prevalent with increasing use of ARSis and is associated with very poor patient clinical outcomes. ZEN-3694 inhibits BRD4 and E2F1 which epigenetically regulate this lineage switch. Blocking BET bromodomain proteins in cell models stopped the activation of this program that drives the development of neuroendocrine prostate tumors, the research team found. Furthermore, this was supported by clinical data from ZEN-3694 Phase 1b/2a mCRPC study which showed that ZEN-3694 was most effective in patients whose tumors were less dependent on androgen receptor signaling and did not respond to prior ARSi. High expression of BRD4 and E2F1 were also observed in the tumors of two patients with treatment emergent neuroendocrine prostate cancer, and both patients had a response to ZEN-3694 + enzalutamide, consistent with the role of ZEN-3694 in overcoming resistance to ARSi in this aggressive form of prostate cancer.
공시 • Mar 17Zenith Epigenetics Announces Dosing of First Mcrpc Patient with A Combination of Zen-3694 + Merck's Immune Check Point Inhibitor KeytrudaZenith Epigenetics Ltd. announced the dosing of first patient with a triple combination of ZEN-3694 + Merck's immune check point inhibitor, KEYTRUDA, + Pfizer's androgen receptor signaling inhibitor (ARSI), XTANDI, in a University of California, San Francisco (UCSF) investigator led metastatic castration resistant prostate cancer (mCRPC) Phase 2 clinical trial. ZEN-3694, the Company's lead therapeutic compound, is being developed for epigenetic combination therapies in multiple oncology indications. This clinical trial will evaluate the aforementioned triple combination therapy in mCRPC patients that have become resistant to 1st a 1 line ARSI therapy. These patients have a very poor prognosis and have a significant need for non-chemotherapies. This study is being supported in part by a research grant from the Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
공시 • Oct 06Zenith Epigenetics Announces Collaboration with Nci in Developing Zen-3694 for Multiple Oncology IndicationsZenith Epigenetics Ltd. announced the execution of a cooperative research and development agreement with the National Cancer Institute to develop ZEN-3694 for multiple oncology indications. For the first clinical study under the CRADA, NCI is co-collaborating with Zenith and Bristol Myers Squibb to investigate the combination of Zenith’s epigenetic therapy BET inhibitor ZEN-3694 with immuno-oncology therapies – checkpoint inhibitors nivolumab and ipilimumab – in resistant ovarian cancer.
공시 • Oct 04Zenith Capital Corp. to Report Fiscal Year 2020 Results on Oct 12, 2020Zenith Capital Corp. announced that they will report fiscal year 2020 results on Oct 12, 2020
공시 • Jul 19+ 3 more updatesZenith Capital Corp. Auditor Raises 'Going Concern' DoubtZenith Capital Corp. filed its Annual on Aug 25, 2014 for the period ending Apr 30, 2014. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.